Sydney Children's Hospital

Sydney NSW 2031

1 studies enrolling now · 8 studies all time

What they study most

ALL, AML, Acute Lymphoblastic Leukemia, Acute Undifferentiated Leukemia, Alport Syndrome, BPDCN, Childhood Solid Tumor, Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Ependymoma, Recurrent Childhood, Hematologic Malignancy, Hodgkin Lymphoma

Studies at this site

• Combination Therapy for the Treatment of Diffuse Midline Gliomas — Recruiting now
• Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies — Recruiting now
• A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Alport Syndrome - CARDINAL — Completed
• COZMOS:Phase I/Ib Trial of Combined 5'Azacitidine and Carboplatin for Recurrent/Refractory Pediatric Brain/Solid Tumors — Completed
• EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL) — Stopped early
• A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma — Completed
• A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL — Stopped early
• Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL — Stopped early